Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.59 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21325603 | 1.00 | CYP2D6 (0.65) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL13975896 | 1.00 | CYP2D6 (0.65) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL24719004 | 0.93 | TLR8 (0.69) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL21325598 | 0.93 | TLR8 (0.69) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL21325639 | 0.87 | CYP2D6 (0.85) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL13975096 | 0.87 | CYP2D6 (0.64) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL13975907 | 0.87 | CYP2D6 (0.85) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL13975722 | 0.87 | CYP2D6 (0.85) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL18109510 | 0.81 | TLR8 (0.69) | CYP2D6TLR8TLR7KCNH2 | |
| SCHEMBL18109508 | 0.81 | TLR8 (0.69) | CYP2D6TLR8TLR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986871-A1 | QUINAZOLINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008029-A | Quinazoline prodrugs for the treatment of viral infections and additional diseases | 爱尔兰詹森科学公司 | 2022-02-01 | — | — | CN | disclosed |